446-60-6Relevant academic research and scientific papers
NITROGEN HETEROCYCLIC COMPOUNDS AND METHODS OF USE
-
Paragraph 1808; 2125, (2021/06/26)
The present disclosure relates to compounds of formula (I): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparing the compounds, compositions comprising the compounds, and methods of using the compounds as inhibitors of receptor tyrosine kinases, in particular oncogenic mutants of ErbB-receptors e.g. in the treatment of cancer.
ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES
-
Paragraph 0156-0158, (2019/12/31)
A compound of Formula (LA)n-M-(LC)m, wherein the ligand LA is of Formula I, and the ligand LC is selected from Formula I that is different than ligand LA, a monoanionic bidentate ligand, or a monoanionic monodentate ligand. M is a metal; and n is 1 or 2, and m is 0, 1 or 2. Ring A is a 5-membered or 6-membered heteroaryl ring, which is bonded to Ring B; Z is selected from O or S; Z1 is selected from a carbene C or N; and Z2 is selected from C or N. Moreover, two adjacent ring carbons of Ring B will form a group of formula D, wherein * represents the point of attachment to the two adjacent ring carbons, Formula D, wherein X is selected from NRN, O, S, or Se; and RN is selected from the group consisting of hydrogen, deuterium, alkyl, cycloalkyl, heteroalkyl, aryl, heteroaryl, and combinations thereof; and Y1, Y2, Y3, and Y4 are independently CRY1, CRY2, CRY3, and CRY4, respectively, or N, and Ring D has no more than two nitrogen ring atoms. An OLED that includes a compound of the Formula I above in an organic layer is also described.
